- Business Wire•yesterdaySHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Khang & Khang LLP announces that it is investigating claims against Alnylam Pharmaceuticals, Inc. concerning possible violations of federal securities laws.
- Benzinga•2 days ago
Piper Jaffray reiterated its Overweight rating and $106 target price on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) despite discontinuation of ENDEAVOUR trial of Revusiran as it sees value in the company’s ...
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||37.21 x 100|
|Ask||37.28 x 300|
|Day's Range||36.36 - 38.12|
|52wk Range||33.16 - 110.75|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-8.81|
|Avg Vol (3m)||1,131,363|
|Dividend & Yield||N/A (N/A)|